We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Synairgen Begins Dosing in Phase 3 Trial of Inhaled COVID-19 Treatment
Synairgen Begins Dosing in Phase 3 Trial of Inhaled COVID-19 Treatment
UK drugmaker Synairgen has dosed the first patient in a global phase 3 trial evaluating an inhaled formulation of interferon beta-1a, SNG001, for treating hospitalized COVID-19 patients who require supplemental oxygen.